Treatment
Dupilumab clinical trials
We’re tracking 55 recruiting studies that include Dupilumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06116526RecruitingPhase 4
Reducing Dupixent in kids with well-controlled eczema
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Baltimore, MarylandAges 1–17 - NCT07091175RecruitingPhase 2
Dupilumab for nephrotic syndrome in children
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Singapore, SingaporeAges 6–18 - NCT07612878Recruiting
Registry tracking COPD patients starting dupilumab treatment
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
Indianapolis, IndianaAges 40 years+ - NCT07112378RecruitingPhase 3
Study of dupilumab for young children with eosinophilic esophagitis
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Phoenix, ArizonaAges 6 months–6 years - NCT06868212RecruitingPhase 3
Testing remibrutinib vs dupilumab for chronic hives
This study compares two oral medications, remibrutinib and dupilumab, to see which works faster for chronic hives that don't get better with standard antihistamines. You may be eligible if you have had hives and itching for at least 6 months and they are still active despite daily antihistamines.
Birmingham, AlabamaAges 18 years+ - NCT06743581Recruiting
Cemiplimab and dupilumab before lung cancer surgery
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Montreal, QuebecAges 18 years+ - NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
BolognaAges 6 months–17 years - NCT06191315Enrolling by invitationPhase 3
Dupilumab for asthma and wheezing in young children
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Phoenix, ArizonaAges 2–5 - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT04743791RecruitingPhase 4
Dupilumab study for clearing mucus in moderate to severe asthma
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT05246267Recruiting
Dupilumab study for chronic sinus disease with nasal polyps
This study looks at how dupilumab (an injection medicine) helps people with chronic rhinosinusitis with nasal polyps, including how well it works across different ethnic backgrounds. You may be able to join if you’ve been diagnosed and you can get dupilumab through insurance or a patient assistance program.
The Bronx, New YorkAges 18–99 - NCT04869436RecruitingPhase 4
Dupilumab to improve smell in nasal polyps
This trial studies whether dupilumab can improve smell in adults whose nasal polyps are causing long-lasting smell loss. It may help learn how well the treatment restores smell, so future patients can benefit sooner.
London, OntarioAges 18 years+ - NCT06398873Recruiting
Dupilumab and nasal lining in chronic sinusitis with polyps
This study tests whether dupilumab, a medication given as an injection, helps improve the lining of the nose in people with chronic sinus inflammation and nasal polyps. If you have nasal polyps and are about to start dupilumab, or if you have sinusitis without polyps, you may be eligible to join.
Vienna, AustriaAges 18–99 - NCT07276425Recruiting
Dupilumab for prurigo nodularis: long-term effects
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
Utrecht, UtrechtAges 18 years+ - NCT06293053RecruitingPhase 3
Study of Dupilumab in children with prurigo nodularis
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
Palo Alto, CaliforniaAges 6 months–17 years - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT05094570RecruitingPhase 4
Dupilumab for nasal polyps with staph bacteria
This trial studies whether dupilumab (an injection) can reduce staph bacteria in the nose and make the nose’s microbes more diverse in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). If you already have a plan to start dupilumab as standard care, the study may help doctors better understand why it works.
Charlottesville, VirginiaAges 18–65 - NCT05268107RecruitingPhase 4
Study dupilumab skin effects in different ethnic groups
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Ann Arbor, MichiganAges 18 years+ - NCT05551793RecruitingPhase 2
Dupilumab for patchy hair loss with scalp inflammation
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
Irvine, CaliforniaAges 18 years+ - NCT05649098RecruitingEarly Phase 1
Testing dupilumab for itchy inherited genetic skin disorders
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
Chicago, IllinoisAges 6 months+ - NCT05858619RecruitingPhase 4
Study of skin response to dupilumab in eczema
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
San Francisco, CaliforniaAges 18 years+
What Dupilumab is being studied for
Conditions with recruiting Dupilumab studies.
Common questions
- Are there clinical trials studying Dupilumab?
- Yes. Clin2 currently lists 55 recruiting studies that include Dupilumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dupilumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dupilumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dupilumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.